Fam-Trastuzumab Deruxtecan-nxki is a targeted cancer therapy also known by its brand name, Enhertu. It is a combination of an anti-HER2 monoclonal antibody (trastuzumab) and a topoisomerase I inhibitor (deruxtecan). This antibody-drug conjugate (ADC) is designed to deliver cytotoxic chemotherapy directly to cancer cells that overexpress the HER2 protein, minimizing damage to normal cells.
